Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
( { s) x" K. F; s: F
) L' s9 b+ s6 m6 d& y4 d" ]9 S
( P" a8 a! r- Q, ~Sub-category:1 d/ f* K+ H. L
Molecular Targets
; b" _2 `# O4 A$ r5 D& ~$ L
4 X" U5 U4 X4 U! p5 [. U1 b$ n/ e
1 R, E# W7 m T0 _$ m1 SCategory:
& ?/ n1 p9 ^4 nTumor Biology $ m7 T& R" n7 b- C. t8 J
4 s' f. G3 p- K) @0 O
3 H# C8 e% X* @: r3 `+ tMeeting:- }$ k9 Y! c6 U4 I
2011 ASCO Annual Meeting
. q- C* o: }9 J% ^8 f, a! | @7 N |0 z: k8 g( r; ^
' Y: m F2 f* e3 s4 f( M: U9 PSession Type and Session Title:0 f, ^3 }4 q# y6 [& j
Poster Discussion Session, Tumor Biology 7 L' r5 U; }: q G. [5 x
) h0 Y% V% P& x* v5 `
( k. W+ D0 y/ r
Abstract No:- |* d$ E% ? r/ K! @9 J; M0 P9 t
10517
. v3 e0 a+ I# j8 p6 n* {3 B* B1 s0 G' S1 ? t
# c* e- M% G' R DCitation:) A1 K# \* T% X7 r' P) g
J Clin Oncol 29: 2011 (suppl; abstr 10517) 6 {! B- b: {* |: P( |
4 Q1 {$ O" C3 H6 w) _
6 p) ]8 S6 o4 P2 F% zAuthor(s):
9 k: O0 j3 [5 X" ~8 B2 P! }J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
, Z1 A7 F* b4 A# X
% ^, s$ p; M9 z5 l
% Q+ P- i3 Q2 U0 i3 _& c0 i% b9 P$ a. C8 p, ~
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.. j, U* c1 Q- g+ Q& ]! X
& S9 U0 G' k0 i# ^* d1 \+ A/ JAbstract Disclosures- M7 W& W# D. Y
, [: _5 n6 K; Y! {4 v- V+ s
Abstract:, d; d3 u9 `# R0 a8 t9 v+ N
" t/ V' m5 c: W/ T7 N5 R+ z( }$ d v
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.5 W6 f- f* q) k' ?: y
" ~4 @7 e% i$ b3 W, B9 x8 B! E9 A1 O
0 `4 F: J$ {! C. Y0 t |
显身卡
